CRYOPORT, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
CRYOPORT, INC. (CYRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 80.30% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2026-08-06
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2026-03-31 was 78.40%, a 5.43% decline year-over-year.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2025-03-31 was 82.90%, a 19.28% increase year-over-year.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2024-03-31 was 69.50%.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2022-03-31 was 76.80%, a 4.95% decline year-over-year.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2025 was 82.90%, a 10.68% increase from fiscal 2024.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 74.90%, a 6.38% decline from fiscal 2023.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 80.00%, a 1.78% increase from fiscal 2022.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 78.60%, a 2.72% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 80.30% 10-Q · filed 2026-08-06 | |||||
| 2026-03-31 | 78.40% 10-Q · filed 2026-05-05 | |||||
| 2025-12-31 | 82.90% 10-K · filed 2026-03-05 | |||||
| 2025-09-30 | 82.90% 10-Q · filed 2025-11-06 | |||||
| 2025-06-30 | 82.90% 10-Q · filed 2026-08-06 | |||||
| 2025-03-31 | 82.90% 10-Q · filed 2026-05-05 | |||||
| 2024-12-31 | 74.90% 10-K · filed 2026-03-05 | |||||
| 2024-09-30 | 74.90% 10-Q · filed 2025-11-06 | |||||
| 2024-06-30 | 70.50% 10-Q · filed 2025-08-12 | |||||
| 2024-03-31 | 69.50% 10-Q · filed 2025-05-08 | |||||
| 2023-12-31 | 80.00% 10-K · filed 2026-03-05 | |||||
| 2023-09-30 | 80.00% 10-Q · filed 2023-11-09 | |||||
| 2023-06-30 | 76.20% 10-Q · filed 2023-08-09 | |||||
| 2022-12-31 | 78.60% 10-K · filed 2025-03-07 | |||||
| 2022-09-30 | 76.80% 10-Q · filed 2023-11-09 | 78.60% 10-Q · filed 2022-11-04 | ||||
| 2022-06-30 | 76.80% 10-Q · filed 2023-08-09 | 78.60% 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | 76.80% 10-Q · filed 2023-05-04 | |||||
| 2021-12-31 | 80.80% 10-K · filed 2024-03-13 | |||||
| 2021-09-30 | 80.80% 10-Q · filed 2022-11-04 | |||||
| 2021-06-30 | 80.80% 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | 80.80% 10-Q · filed 2022-05-05 | |||||
| 2020-12-31 | 82.70% 10-K · filed 2023-02-28 | |||||
| 2020-09-30 | 82.30% 10-Q · filed 2020-11-06 | |||||
| 2020-06-30 | 77.30% 10-Q · filed 2020-08-10 | |||||
| 2020-03-31 | 77.30% 10-Q · filed 2020-05-08 | |||||
| 2019-12-31 | 99.20% 10-K · filed 2022-02-28 | |||||
| 2019-09-30 | 99.20% 10-Q · filed 2019-11-12 | |||||
| 2019-06-30 | 99.00% 10-Q · filed 2019-08-09 | |||||
| 2019-03-31 | 99.00% 10-Q · filed 2019-05-09 | |||||
| 2018-12-31 | 110.00% 10-K · filed 2020-03-10 | |||||
| 2017-12-31 | 115.00% 10-K · filed 2019-03-13 | |||||
| 2015-03-31 | 128.00% 10-K · filed 2015-05-19 | |||||
| 2014-06-30 | 125.30% 10-Q · filed 2014-07-31 | |||||
| 2014-03-31 | 140.00% 10-K · filed 2015-05-19 | |||||
| 2013-12-31 | 140.00% 10-Q · filed 2014-02-13 | |||||
| 2013-09-30 | 137.00% 10-Q · filed 2013-11-18 | |||||
| 2013-06-30 | 135.00% 10-Q · filed 2013-08-14 | |||||
| 2013-03-31 | 166.00% 10-K · filed 2013-06-25 | |||||
| 2012-12-31 | 166.00% 10-Q · filed 2014-02-13 | |||||
| 2012-09-30 | 166.00% 10-Q · filed 2013-11-18 | |||||
| 2012-06-30 | 159.00% 10-Q · filed 2013-08-14 | |||||
| 2012-03-31 | 173.00% 10-K · filed 2013-06-25 | |||||
| 2011-06-30 | 173.00% 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |